å»è¬åå ¬è¡šãããæŽå¯
å¯è çæ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ã®USD 310,000,000ã§äŸ¡å€ããããšæšå®ãããå šäœçãªAdrenocortical Carcinomaã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯2032幎ãŸã§ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ã2025ãã2032幎ãŸã§æºãããšæåŸ ãããŸãããããã£ãŒã«å¯è çæ²»ç補åã¯ãè «çã®æé·ãå¶åŸ¡ããããã«èšèšãããŠããŸã, ãã«ã¢ã³ã®åæ³ãæžãããŸã, çåçãåäžããã. æšæºçæ³ã«ã¯ããšããã·ãããããœã«ãã·ã³ãã·ã¹ãã©ãã³ãªã©ã®ååŠçæ³ãããã³èšåºéçºã«ãããæšççæ³ãå«ãŸããŸãã PD-1é»å®³å€ãå«ãå ç«çæ³ã¯ãé«åºŠçäŸã«ãããæ£è ã®ææãé«ã... ãã£ãšèŠã
Dravetçå矀治çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ãã2032幎ãŸã§ã®USD1.2åç±³ãã«ã§äŸ¡å€ãæåŸ ãããã°ããŒãã«Dravetã·ã³ãããŒã æ²»çåžå ŽèŠæš¡ã¯ã2032幎ãŸã§ã«2åç±³ãã«(USD 2.8å)ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®13.5%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«DravetçåçŸ€ã®æ²»çã¯ãé床ã®ãè¬ç©èæ§ã®ç«ç ãæäžããããšã«çŠç¹ãåœãŠãŠããŸãã 補åããŒããã©ãªãªã«ã¯ãé²é£è¬(AED)ãã«ã³ãããã€ãããŒã¹ã®æ²»çè¬ãããã³éºäŒåæšçæ²»çãå«ãŸããŠããŸãã æ¹æå€ããã§ã³ãã«ã¢ãã³ãã«ã³ãããžãªãŒã«ãªã©ã®FDA... ãã£ãšèŠã
ç¬¬äžæ¬¡æ§è硬å€å»è¬ååžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžçã®ç¬¬äžæ¬¡èå¢èçã®è¬å€ åžå ŽèŠæš¡ã¯2025幎ã«1,35åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«2,12åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã«6.3%ã®é£çµå¹Žéæé·ç(CAGR)ãå ããŠããŸãããããã£ãŒã«PBCå»è¬åã«ã¯ãæ ¢æ§èªå·±å ç«ã®ç®¡çãç®çãšããæ²»ç補å€ãå«ãŸããŸã èçŸæ£ ç æ°ã®é²è¡ãé ãããèæ±é žã®èç©ãæžããããšã«ãã£ãŠã äž»èŠãªãããã¯ã ã¿ã€ãã¯å°¿çŽ é ž(UDCA)ãfarnesoid Xã®å容åš(FXR)ã®ãããªèæ±é žã®ã¢ããã°ããã³PPARã®ã¢ãŽãã¹ãããã³å ç«èª¿ç¯åšã®ãããªæ°èã®åŠçœ®ãå«ãã§ããŸ... ãã£ãšèŠã
Clostridioidesã®æ¡æ£åšã®ææçã®åŠçœ®ã®åžå Žã¯USD 1,024.9ã§äŸ¡å€ããããšæšå®ãããŸã 2025幎ã®Mnã¯USD 1,659.8ã«éãããšäºæ³ããã 2032幎ã®Mnã¯ã2025幎ãã2032幎ã«ãããŠ7.13%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãã Clostridiodesã®difficileã®äŒæã¯ã³ãã³ã®å éšã®ã©ã€ãã³ã°ã«ææããäžç¢ããã³è¡çªãåŒãèµ·ãããŸã(ã³ãã³ã®çç)现èã§ãã è žå ã®æ£åžžãªãå¥åº·ãªçްèã®åŠšå®³ãæçç©è³ªã®çµæãšããŠé »ç¹ã«ãClostridiumã®æ¡æ£æ§çã«ã€ãªãããŸãã ãŸããäžäººããå¥ã®äººã«C.ã®å·®ç°ãåºããããšãå¯èœã§ãã ã³... ãã£ãšèŠã
Cåèçè¬åžå ŽèŠæš¡ãæåŸ ããã 2025幎ã®US $ 9.86åãã2032åç±³ãã«ã§13,24åç±³ãã«ã§4.3%å¢å äºå ±æéäžã èç Cã¯ã ãã€ã©ã« ççãšåŒã°ããèèã®è «ããåŒãèµ·ããææçã èç Cã¯æ·±å»ãªèèã®æå·ã«ã€ãªããããšãã§ããŸãã CåèçãŠã€ã«ã¹(HCV)ã¯ããŠã€ã«ã¹ã«ææããè¡æ¶²ãšæ¥è§Šããããšã§åºãããŸããèçã®çç¶ Cã¯ç±ãéåžžã«ç²ãã飿¬²ã®åªå€±ãåãæ°ããã³ååãè ¹éšã®çã¿ãæãå°¿ãæ·¡ãé¡ãé¢ç¯ã®çã¿ãããã³é»çž(ç®èãç®ã®é»è²)ãå«ã¿ãŸããCåèçè¬ åžå Žå°åæŽå¯:åã¢ã¡ãªã« 2025幎ã®åžå Žã·ã§ã¢ã®40.6%以äžãå ããäºæž¬æéäžã«Cè¬ãèçã®ããã«æå€§ã®... ãã£ãšèŠã
ã¢ã¯ãã¡ããªãŒæ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã¢ã¯ãã¡ããªãŒæ²»çåžå ŽèŠæš¡ã¯ã2025幎ã®USD 1.45åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 2.34åã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®6.8%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«ã¢ã¯ãã¡ã¬ãªãŒæ²»ç補åã¯ãäžåäœè «çã«ãã£ãŠåŒãèµ·ããããæé·ãã«ã¢ã³ã®éå°ç£çã管çããããã«éçºãããå»è¬å補å€ã§ãã ãããã¯ãœããã¹ã¿ãã³ã®ã¢ããã°ãæé·ãã«ã¢ã³ã®å容åšã®å察è ãããã³ããŒããã³ã®ã¢ãŽãã¹ããå©çšã§ããæ³šå°å¯èœãªãå£é 圢æ ãå«ãã§ããŸãã ãªã¯ãã¬ãããã©ã³ã¬ãªãããããã³ãã°... ãã£ãšèŠã
èäžã®çã¿ æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ã»ããã¯ã»çã¿ ã»ã©ã㌠åžå ŽèŠæš¡ã¯2025幎ã®USD 9.8åã§è©äŸ¡ããããšæšå®ããã2032幎ã«16.4åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®7.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«èäžã®çã¿çæ³ã¯ãçã¿ãç·©åããéåãæ¹åããçéªšæ Œæ©èœãå埩ããããšãç®çãšãã補åãä»å ¥ã®å¹ åºãé åã䌎ããŸãã NSAIDãçèåŒç·©å€ããªããªã€ããªã©ã®è¬çåŠçæ²»çãç©ççæ³ãã«ã€ããã©ã¯ãã£ãã¯ã±ã¢ãæŽåœ¢å€ç§æè¡ãããã³æå°éã®äŸµè¥²çåŠçœ®ãå«ãã é«åºŠãªçæ³ã«ã¯ãæŸå°ç·é »åºŠã®ã¢ãã¬ãŒã·ã§... ãã£ãšèŠã
Angioedema æ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2025 â 20322025幎ãã2032幎ãŸã§ã®å¹Žéæé·ç(CAGR)ã®9.4%ãå ãã2032幎ãŸã§ã®USD 2.3åãã«ã«éãããšäºæ³ãããŸãããããã£ãŒã«Angioedemaæ²»ç補åã¯ãã¢ã¬ã«ã®ãŒåå¿ãéºäŒçæ¬ ä¹ããŸãã¯è¬ç©å¯äœçšã«ãã£ãŠåŒãèµ·ãããã屿çãªè «ãã®æ¥æ§ããã³æ ¢æ§ã®ãšããœãŒãã管çããããã«èšèšãããŠããŸãã æ²»çç¯å²ã¯ãæãã¹ã¿ãã³å€ãã³ã«ãã³ã¹ããã€ããC1ãšã¹ãã«ã¢ã»ã¿ãŒãŒé»å®³å€ã®æ¿çž®ç©ãbradykininåå®¹äœæ®æè¬ãããã³ã¢ãã¯ããŒãã«æäœãå«ã¿ãŸãã æ²»çã¯ãçµå£ã泚å°å¯èœãªãããã³éçããã³é床ã®åå ã«å¿ã... ãã£ãšèŠã
ç³å°¿ç ãããæœ°çæ²»çåžå Žã¯ã2025幎ã«USD 9.38 Bnã§è©äŸ¡ãããUSD 18.51ã«éãããšäºæ³ããã 2032幎ã«Bnã2025幎ãã2032幎ãŸã§ã®10.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã ã°ããŒãã«ç³å°¿ç ãããæœ°çæ²»çåžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:審çŸçãªããããããžã¡ã³ãã®ã¢ãããŒãã¯ãç¬¬äžæ¬¡ããã³ç¬¬äºæ¬¡å»çã§ç°ãªããŸãã ããããå»åž«ã¯èšºæããŒã«ã䜿çšããŠãç³å°¿ç ã®æ§è³ªãšéç床ãè©äŸ¡ããŸãã ç³å°¿ç ã®è¶³ã®ç®¡çã§èšç·Žãããå»åž«ã¯ãæåããæåçã§ãæ£è ãåæçã«ç®¡çã§ããããã«å ±åãããŠããŸãã ç³å°¿ç ãããæè²ããã°ã©ã ãšåœæ°ãããã±ã¢ã¬ã€ãã©ã€ã³ã®èŠå®ã«ããããã... ãã£ãšèŠã
Stargardtã®ç æ°ã®æ²»çè¬ åžå Žã¯ç±³ãã«488.7ã§äŸ¡å€ããããšæšå®ããã 2025幎ã®Mnã¯USD 3,358.5ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ31.7%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã Global Stargardtã®ã¢ããªã¹ãã®ãã¥ãŒ ç æ°ã®æ²»çè¬ åžå Ž:äžççãªã¹ã¿ãŒã¬ãŒããçŸæ£æ²»çåžå Žã¯ãåéã«æ°ããæè¡ãšé©æ°ãç«ã¡äžããŠããäž»èŠãªãã¬ãŒã€ãŒã®é¢äžã«ããè¿ãå°æ¥ã«æ°èãããææ¬²çãªæé·ã§ãã ãããã®äž»èŠãªãã¬ãŒã€ãŒã¯ãã¹ã¿ãŒã¬ãŒãç ã®ããã®å¹æçãªæ²»çãšæ²»çãèŠã€ããããã«ç ç©¶éçºã«å€§ããæè³ããŠããŸãã ããŸããŸãªçµç¹ãæ¿åºã®åã... ãã£ãšèŠã
å°å æ é€åžå Žã¯2025幎ã®USD 4.49 Bnã§è©äŸ¡ãããUSD 6.93ã«éãããšäºæ³ããã 2032幎ã«Bnã2025幎ãã2032幎ã«ãããŠ6.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã ãããã®è£œåã¯ããã«ã¯ããŒã¹ã倧è±ããŒã¹ãã¢ããé žããŒã¹ãææ©åœ¢æ ã§å©çšå¯èœã§ãã ãããã®æ é€è£œåã¯ãè³ã®éçºããµããŒãããã¢ã¬ã«ã®ãŒã代è¬é害ã®ç®¡çã«ã圹ç«ã¡ãŸãã 2017幎ãã¢ãžã¢ã»ãã·ãã£ãã¯ã§æå€ã®åºçåæ°ãèšé²ãããã以éã¯åžå Žãã¬ã€ã€ãŒã«ãšã£ãŠæå€§ã®æ©äŒãä¿æããŠããŸãã ãã®ãããMead Johnson Nutrition(Reckitt Benckiser Group plc)ã... ãã£ãšèŠã
ãã€ç æ²»çè¬åžå Žã¯ã2025幎ã«USD 14.09 Bnã§è©äŸ¡ãããUSD 19.17ã«éãããšäºæ³ããã 2032幎ã«Bnã2025幎ãã2032幎ãŸã§ã®4.5%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã ã°ããŒãã«ã»ããã¬ãã·ã§ã³ã»ã»ã©ãã¥ãŒãã£ã¯ã¹ã»ããŒã±ããã®ã¢ããªã¹ãã»ãã¥ãŒ:åžå Žãã¬ãŒã€ãŒã¯ãåžå Žã§æ°ããè¬ã®ç ç©¶ãšéçºã«çŠç¹ãåœãŠãŠããŸã, ã°ããŒãã«ãªãã€ç ã®æ²»çåžå Žã®æé·ãé§åããããšãæåŸ ãããŠããŸã. ããšãã°ã2022幎12æã«ã¯ã補è¬äŒç€Ÿã§ãã倧å¡è£œè¬éçºã»ååå(Inc.)ãšè£œè¬äŒç€Ÿã§ããSunovion Pharmaceuticals, Inc.(Sanovion Ph... ãã£ãšèŠã
Hdacé»å®³å€ åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«Hdacé»å®³å€ åžå ŽèŠæš¡ã¯2025幎ã«2åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«5.6åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®10.7%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«HDACé»å®³å€ã¯ããã¹ãã³ãã¢ã»ãã©ã¹ããããã¯ããããšã§éºäŒåçºçŸã調ç¯ããå»è¬åååç©ã§ãããã¯ãããã³æ¹é ã«é¢ããé µçŽ ã§ãã ãããã®è£œåã¯ãäž»ã«æããæ²»çè¬ãšããŠéçºããããªã³ãè «ãå€çºæ§çè «ãªã©ã®è¡æ¶²ãããæšçãåºäœè «çãšããŠéçºãããŠããŸãã æ¬¡äžä»£HDACé»å®³å€ã¯ãç¥çµçŸæ£ããŸããªéºäŒçŸæ£ãããã³äœµçšçæ³ã®ã... ãã£ãšèŠã
ã»ã«ããŒã¹ã®ã¢ãã»ã€åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ã»ã«ããŒã¹ã®ã¢ãã»ã€åžå ŽèŠæš¡ã¯ã2025幎ã®USD 6.8åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã«14.5åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®11.5%ã®ã³ã³ããŠã³ã幎éæé·ç(CAGR)ã瀺ãããããã£ãŒã«çްèããŒã¹ã®ã¢ãã»ã€ã¯ãç现èã䜿çšããŠãååç©ã®äœçšã®çç©åŠç掻æ§ãæ¯æ§ããŸãã¯ã¡ã«ããºã ãè©äŸ¡ããå®éšå®€æè¡ã§ãã éé¢ãããååã«äŸåããçååŠçã¢ãã»ã€ãšã¯ç°ãªãããããã®ã·ã¹ãã ã¯çްèã®è€éããç¶æããç ç©¶è ã¯ãè¬ç©ãçç©åŠçè«çããŸãã¯ä»ã®ãšãŒãžã§ã³ããã©ã®ããã«äœçšããçµè·¯ã墿®ã... ãã£ãšèŠã
ã¬ãŠãã£ãŒç æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ãã2032幎ã«ãããŠãäžçã¬ãŠãã£ãŒç æ²»çåžå ŽèŠæš¡ã¯2025åç±³ãã«ã«çžåœãããšæšå®ããã2032幎ãŸã§ã®6.5%ã®ååç©å¹Žéæé·ç(CAGR)ã瀺ãããããã£ãŒã«Gaucherã®ç æ°ã®åŠçœ®ãããã¯ãã¯äž»ã«äžå©ãªã°ã«ã³ã©ãŒãŒãvelagluceraseã¢ã«ãã¡ãããã³taligluceraseã¢ã«ãã¡ã®ãããªé µçŽ ã®åãæ¿ãã®çæ³(ERTs)ããããã£ã®èèªç©è³ªãç Žå£ããããã«deficientã®ã°ã«ã³ã»ã¬ãããžããŒãŒã®é µçŽ ãåãæ¿ããããšã«ãã£ãŠåããŸãã ããäžã€ã®ã«ããŽãªã¯ããã°ã«ã¹ã¿ããããšãªã°ã«ã¹ã¿ããã®ãããªåºè³ªæž... ãã£ãšèŠã
çã®åŒåžåšçŸæ£æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ã®USD 2.15åç±³ãã«ã§äŸ¡å€ããããšæšå®ããã2032幎ãŸã§ã«USD 3.67åç±³ãã«ã«éãããšäºæ³ãããŸãããããã£ãŒã«çã®åŒåžåšææç(BRD)ã®æ²»çã¯ãè«æ¯ã®ææãé²ãã管çããæ²»çããããã«èšèšãããç£å»è£œåã®ç¯å²ãå å²ããŸãã ãããã®ææçã¯ãäžè¬çã«ãŠã€ã«ã¹ãšçްèã®ç åäœã®çµã¿åããã«ãã£ãŠåŒãèµ·ããããŸã, å€ãã®å Žåã茞éãç°å¢ã®å€åãªã©ã®ã¹ãã¬ã¹èŠå ã«ãã£ãŠæªåããŸã.å©çšå¯èœãªè£œåã¯ããŠã€ã«ã¹ããã³çްèã®ä»£çåºãçŽ°èææãå¶åŸ¡ããããã«äœ¿çšãããæèçæ³ãããã³ç±ããã³èºã®ççãæžããã®ã«åœ¹ç«ã€æç... ãã£ãšèŠã
äž»èŠãªãã€ç å€åŠçåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ã«18.7åç±³ãã«ã«çžåœããäžççãªäž»èŠãªãã€ç å€åŠçåžå ŽèŠæš¡ã¯æšå®ããã2032幎ãŸã§ã«33.3åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®8.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ã瀺ãã ãã®å°è±¡çãªæ¥çèŠæš¡ãšäºæž¬ã¯ãäžççãªæé·çãšåŒ·åãããèšºææ©èœã«ãã£ãŠé§åãããå ç¢ãªåžå Žæé·ã匷調ããçŸåšãåç±³ã§ã¯éèŠãªæ¥çã·ã§ã¢ãä¿æããŠããŸãããããã£ãŒã«äž»èŠãªãã€ç å€(MDD)ã®åŠçœ®ã¯SSRIsãSNRIsãtricyclicã®æé¬±å€ãMAOIsããã³esketamineã®éŒ»ã®ã¹ãã¬ãŒã®ãããªããæ°ããéãæ©... ãã£ãšèŠã
ã°ããŒãã«å°¿è·¯ææçæ²»çåžå Žã¯ãè©äŸ¡ããããšæšå®ãããŸã 2025幎ã®USD 9.4 Bn å±ç€ºäºå® 3.20%ã®CAGR äºå ±æéäž (2025-2032)ãåãåããäžççãªå°¿è·¯ææçæ²»çåžå Žã¯ãäžçäžã®ç³å°¿ç ãšè èã®ç³ã®é«åçã«ãã匷åãªæé·ãçµéšããŠããŸãã ãŸããå°¿è·¯ææç(UTI)ã®äºé²å¹æãé«ããäžçåå°ã®èã®äººå£ãå¢å ãããããšã§ãåžå Žã®æé·ãä¿ãããšãæåŸ ãããŠããŸãã ããããªãããUTIè¬ã®äœ¿çšã«é¢é£ããæªåœ±é¿ããäººã®æèã®æ¬ åŠãªã©ã®èŠå ã¯ãå°¿è·¯ææçã®æ²»çäžã®åžå Žã®æé·ã劚ããããšãæåŸ ãããŠããŸããã°ããŒãã«å°¿è·¯ææçæ²»çåžå Ž: å°åã€ã³ãµã€ãå°ççã«åºã¥ããŠãäžçç... ãã£ãšèŠã